PCSK9 and type 2 diabetes mellitus: Furthermore, proprotein convertase subtilisin kexin type 9 (PCSK9) may have effects in lipid metabolism and β-cell function in T2DM, and use of anti-PCSK9 monoclonal antibodies has a potential to prevent new-onset diabetes in the future, although the evidence is currently lacking [55].